---
id: 169
title: Coccidioides Species (Coccidioidomycosis)
category: organisms
subcategory: endemic_fungi
tags: [Coccidioides, valley-fever, Southwest, fluconazole, spherules, eosinophilia]
difficulty: medium
---

## Question

What are the key clinical syndromes and treatment of coccidioidomycosis? Use the **"Southwest US, Valley Fever (Self-Limited), High-Risk: Dissemination (Filipinos, Pregnant, AA) → Fluconazole"** framework.

## Answer

### ***Coccidioides* Species Overview:**

**Geography:**
- **Endemic:** Southwestern US (Arizona, California Central Valley, New Mexico, Texas), Mexico, Central/South America
- **Soil** (arid, alkaline, desert regions)

**Transmission:** Inhalation of arthroconidia (airborne spores) - disruption of soil (construction, dust storms, earthquakes)

**High-Risk Groups for Dissemination:**
- **Race/ethnicity:** Filipino, African American (5-10× higher risk)
- **Pregnancy** (especially 3rd trimester)
- **Immunosuppression:** HIV (CD4 <250), transplant, TNF-α inhibitors, high-dose steroids
- **Diabetes**

### **Clinical Syndromes:**

**Primary Pulmonary Coccidioidomycosis ("Valley Fever"):**

**Presentation:**
- **Asymptomatic:** 60% (incidentally discovered on serology/CXR)
- **Symptomatic (40%):** Flu-like illness (1-3 weeks after exposure)
  - **Fever, cough, chest pain, fatigue, night sweats, headache**
  - **Erythema nodosum** (tender red nodules on shins) - 10-15% of women, 5% of men
  - **Erythema multiforme** (target lesions)
  - **Arthralgias** ("desert rheumatism")

**CXR:**
- **Hilar/mediastinal lymphadenopathy**
- **Infiltrates** (patchy or lobar)
- **Pleural effusion** (10-50%, often eosinophilic)
- **Thin-walled cavities** (can persist for years, usually asymptomatic)

**Outcome:**
- **Self-limited** (95% of immunocompetent, resolves in weeks to months)

**Chronic Progressive Pulmonary:**
- **Persistent or progressive** symptoms (months)
- **Cavities, nodules, fibrocavitary disease** (mimics TB)
- **Requires treatment**

**Disseminated Coccidioidomycosis (5% of Infections, Higher in High-Risk):**

**Sites:**
- **Skin:** Papules, nodules, ulcers, verrucous lesions (face, scalp common)
- **Bone/joints:** Osteomyelitis (vertebrae, long bones), arthritis (knee, ankle)
- **CNS (meningitis):** Chronic meningitis (headache, altered mental status, CN palsies)
  - **Fatal without treatment**
  - **CSF:** Lymphocytic pleocytosis, ↑protein, ↓glucose, eosinophils (20-40%)
  - **Basilar meningitis** (can cause hydrocephalus)
- **Other:** Peritoneum, liver, spleen, lymph nodes

**Outcome:**
- **Requires prolonged treatment** (often lifelong in meningitis)

### **Diagnosis:**

**Serology (Preferred Initial Test):**
- **IgM (tube precipitin):** Appears 1-3 weeks, indicates acute infection
- **IgG (complement fixation, immunodiffusion):** Appears 1-2 months, persists
- **High IgG titers (≥1:16):** Suggest disseminated or severe disease

**Histopathology:**
- **Spherules** (20-200 μm) with endospores (pathognomonic)
- **GMS or PAS stain**

**Culture:**
- **Gold standard** (biosafety level 3 required - highly infectious in lab)
- **Slow** (1-3 weeks)

**Antigen Detection:**
- **Urine/serum *Coccidioides* antigen** (EIA)
- **Useful in disseminated disease** (monitor treatment response)

### **Treatment:**

**Primary Pulmonary (Mild, Immunocompetent):**
- **Observation** (self-limited in most)
- **Consider treatment if:**
  - Symptoms >2-3 months
  - Severe symptoms
  - Risk factors for dissemination (Filipino, African American, pregnant, immunosuppressed)

**Primary Pulmonary (Requiring Treatment):**
- **Fluconazole 400mg PO daily × 3-6 months**

**Chronic Progressive Pulmonary / Disseminated (Non-Meningeal):**
- **Fluconazole 400-800mg PO daily × ≥12 months** (bone/joint may require 1-2 years)
- **Severe:** **Liposomal amphotericin B 3-5 mg/kg IV daily** (until clinically improved) → fluconazole

**Meningitis:**
- **Fluconazole 800-1200mg PO daily × lifelong** (most patients)
- **Alternative:** Intrathecal amphotericin B (rarely used, reserved for refractory cases)
- **Voriconazole/posaconazole:** Consider if fluconazole fails
- **Monitor:** CSF eosinophils, serology (titers should decline)

**Pregnancy:**
- **Liposomal amphotericin B** (azoles contraindicated, especially 1st trimester)

**HIV:**
- **Treat as above**, continue ART
- **Secondary prophylaxis:** Fluconazole 400mg PO daily (lifelong, or until CD4 >250 × 6 months on ART)

## Key Points

### **Erythema Nodosum:**
- **Tender red nodules** on shins (hypersensitivity reaction)
- **Good prognostic sign** (indicates robust immune response, low risk dissemination)
- **"Desert rheumatism":** Erythema nodosum + arthralgias

### **Spherules with Endospores:**
- **Pathognomonic** (20-200 μm spherules containing endospores)
- **Unique to *Coccidioides*** (other fungi do NOT form spherules in tissue)

### **Eosinophilia:**
- **Peripheral eosinophilia** (common in acute infection)
- **Eosinophilic pleural effusion**
- **CSF eosinophils** (20-40% in meningitis)

### **High-Risk for Dissemination:**
- **Filipino, African American** (5-10× risk)
- **Pregnancy** (3rd trimester)
- **Immunosuppressed** (HIV CD4 <250, transplant, TNF-α inhibitors)

### **Meningitis = Lifelong Treatment:**
- **Fluconazole 800-1200mg daily × lifelong**
- **Basilar meningitis** (CN palsies, hydrocephalus)
- **CSF eosinophils** (20-40%)

### **Fluconazole Preferred:**
- **Better tolerated** than itraconazole
- **Excellent CSF penetration** (essential for meningitis)
- **Dose:** 400-800mg daily (non-meningeal), 800-1200mg daily (meningitis)

### **Clinical Pearls:**
- **Endemic:** Southwestern US (Arizona, California Central Valley)
- **Valley fever:** Self-limited (95% immunocompetent), treat if >2-3 months or high-risk
- **Erythema nodosum** = good prognosis (robust immune response)
- **High-risk dissemination:** Filipino, African American, pregnant, immunosuppressed
- **Spherules with endospores** = pathognomonic
- **Meningitis:** Fluconazole 800-1200mg daily × lifelong

## Sources

- [IDSA: Coccidioidomycosis Guidelines 2024]
- [CID: Coccidioidomycosis Review 2024]

## Media

N/A
